Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Ensysce Biosciences, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 12 | 9 | −3 |
| Shares | 167.7K | 53.1K | −114.6K (−68.3%) |
| Value | $231.1K | $56.4K | −$174.7K (−75.6%) |
New holders (2)
Institutions that held Ensysce Biosciences, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 10,957 | $12.0K | 0.00% |
| Advisory Services Network, LLC | 347 | $368 | 0.00% |
Sold out (5)
Institutions that held Ensysce Biosciences, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Sabby Management, LLC | 96,973 | $133.8K |
| Citadel Advisors LLC | 19,113 | $26.2K |
| Two Sigma Securities, LLC | 14,616 | $20.2K |
| Bank of America Corp | 59 | $81 |
| Wolverine Asset Management LLC | 12 | $16 |